Enterprise Value

26.75M

Cash

25.71M

Avg Qtr Burn

-6.273M

Short % of Float

0.66%

Insider Ownership

14.67%

Institutional Own.

59.64%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Auxora™ Details
Acute Pancreatitis

Phase 2b

Data readout

Auxora™ Details
Asparaginase-induced pancreatic toxicity

Phase 2

Data readout

Auxora™ Details
Acute Kidney Injury, Kidney disease

Phase 2

Initiation

GB-102 (Pan-VEGF inhibitor) Details
Eye disease , Wet age-related macular degeneration , Age-related macular degeneration

Failed

Discontinued

GB-102 (Pan-VEGF inhibitor) Details
Diabetes, Eye disease , Diabetic macular edema

Failed

Discontinued